PVCT (Provectus Biopharmaceuticals) YoY Rev. per Sh. Growth : 0.00% (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Provectus Biopharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was 0.00%.

Provectus Biopharmaceuticals's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Provectus Biopharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Provectus Biopharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals YoY Rev. per Sh. Growth Chart

Provectus Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY Rev. per Sh. Growth

Get a 7-Day Free Trial

Provectus Biopharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY Rev. per Sh. Growth	Get a 7-Day Free Trial															-	-	-	-	-

Provectus Biopharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Provectus Biopharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY Rev. per Sh. Growth (A: Dec. 2023 )
=	(Revenue per Share (A: Dec. 2023 )	-	Revenue per Share (A: Dec. 2022 ))	/	\| Revenue per Share (A: Dec. 2022 ) \|
=	(0	-	0)	/	\| 0 \|
=	N/A %

Provectus Biopharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=	(Revenue per Share (Q: Sep. 2024 )	-	Revenue per Share (Q: Sep. 2023 ))	/	\| Revenue per Share (Q: Sep. 2023 )) \|
=	(0	-	0)	/	\| 0 \|
=	N/A %

Provectus Biopharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » YoY Rev. per Sh. Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 S Gay Street, Suite 1610, Knoxville, TN, USA, 37929

Website

https://www.provectusbio.com

Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.

Executives

Jeffrey Allen Morris	10 percent owner	1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines	officer: Chief Financial Officer	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing	director	2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass	officer: See Remarks	7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper	officer: Interim CEO, CFO, COO	7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter	director, officer: Chief Technology Officer	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv	director	191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams	10 percent owner	370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott	director, 10 percent owner, officer: President	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931